GI
CRDF icon

GAMMA Investing’s Cardiff Oncology CRDF Stock Holding History

GAMMA Investing’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$191 Sell
147
-1,082
-88% -$1.72K ﹤0.01% 4096
2026
Q1 		$1.99K Buy
1,229
+483
+65% +$992 ﹤0.01% 3669
2025
Q4 		$2.1K Buy
+746
New +$1.73K ﹤0.01% 3586

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GAMMA Investing's CRDF Position: Q2 2026 in Review

GAMMA Investing reduced its Cardiff Oncology (CRDF) stake by 88% in Q2 2026, selling an estimated $1.72K and leaving 147 shares worth $191. The position accounts for ﹤0.01% of the portfolio, ranked #4096.

GAMMA Investing first reported a position in CRDF in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.1K in Q4 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • GAMMA Investing held 147 shares of Cardiff Oncology worth $191 as of Q2 2026.
  • GAMMA Investing sold 1,082 Cardiff Oncology shares in Q2 2026, an estimated $1.72K.
  • Cardiff Oncology made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4096 holding.
  • GAMMA Investing first reported a position in Cardiff Oncology in Q4 2025 and has held it in 3 quarters since.
  • GAMMA Investing's Cardiff Oncology position peaked at $2.1K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.